stockrowRegeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.
- Revenue
- +36.3%
- EPS
- +36.0%
- Free cash flow
- +3.85%
- Total debt
- −26.6%
Quarter to September 2026, against a year earlier
Follow REGN
Alert me
Regeneron Pharmaceuticals, Inc. (REGN) Return on invested capital
Regeneron Pharmaceuticals, Inc.'s return on invested capital over the twelve months to 30 September 2026 was 11.6%, up 2.8 percentage points from fiscal 2025 (8.82%). Over the past ten years it has ranged from 8.82% (fiscal 2025) to 37.1% (fiscal 2021) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 8.82% | (2.00) |
| FY2024 | 10.8% | (3.37) |
| FY2023 | 14.2% | (2.62) |
| FY2022 | 16.8% | (20.33) |
| FY2021 | 37.1% | 15.08 |
| FY2020 | 22.1% | 5.98 |
| FY2019 | 16.1% | (7.72) |
| FY2018 | 23.8% | (0.10) |
| FY2017 | 23.9% | 1.79 |
| FY2016 | 22.1% | (4.21) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 85.2% |
| VRTX Vertex Pharmaceuticals Incorporated compare | 14.9% |
| REGN Regeneron Pharmaceuticals, Inc. | 11.6% |
| GMAB Genmab A/S Sponsored ADR compare | 6.99% |
| RPRX Royalty Pharma PLC compare | 5.24% |
| RVMD Revolution Medicines, Inc. compare | 0.00% |
| ARGX argenex SE compare | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −34.5% |
| MRNA Moderna, Inc. compare | −93.5% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on REGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement